MYC and cancer: In this context, whereas previous results suggest that targeting Fzd9 may not be the best strategy for cancer therapy because of its dual pro- and anti-tumorigenic character (Zeng et al, 2018), our data indicate that it might be at least a valuable target when up-regulated in Myc-driven malignancies.